AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 262 min read$VTRS

Campbell Paul sold $810K of VTRS

Campbell Paul (See Remarks) sold 50,076 shares of Viatris Inc (VTRS) at $16.17 ($0.81M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Campbell Paul
Published Jun 26, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 26, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$VTRS
Neutral
medium confidence
Mentioned
$VTRS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VTRSNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price, and post-transaction holdings; it can marginally influence sentiment but does not change fundamentals by itself.

02

Market read

A scheduled insider sale under 10b5-1 is typically low-signal; any trading impact is likely limited unless part of a broader pattern.

03

What to watch

Traders may over-weight single insider sales; without context on prior insider activity, net selling trend, or concurrent fundamentals, the signal is weak.

Relevance 4/10Novelty 5/10Timing: after-hours/filing time (Form 4 filed 2026-06-26)

Background

The article is an SEC Form 4 insider transaction disclosure for Viatris (VTRS).

Company-level read

Ticker impact

$VTRSNeutralMedium confidence
Context

Viatris insider Campbell Paul sold 50,076 shares at $16.1711 via an open-market transaction under a 10b5-1 plan, per Form 4 filed June 26.

Expected impact

Likely limited near-term price impact; any effect should be small and fade unless followed by additional insider selling or fundamental news.

Evidence & confidence

The filing is a primary-source Form 4, but it specifies a pre-arranged 10b5-1 plan and the article provides no accompanying fundamental catalyst.

Market effects

Sector

No sector read-through; this is company-specific insider transaction data only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than a change in outlook.

Key entities

  • issuer
    Viatris Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Campbell Paul

    Officer who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$VTRSMedAI 8/10

Viatris Lifts 2026 Outlook After Strong Second Quarter

Viatris reported Q2 2026 results on Aug. 6, with total revenue of $3.76B, up 5% YoY, and adjusted EBITDA of $1.2B, up 8% operationally. It posted a U.S. GAAP net loss of $119M. The company cited strong Greater China performance, U.S. FDA approval of Gwyn Lo, Tyrvaya rights sale, raised 2026 guidance midpoints, returned about $550M to shareholders, and cut gross leverage to 2.9x.

theglobeandmail.com6 min
AUG 6
$VTRSMed

Viatris Slides Despite Higher 2026 Guidance as Supply Disruption Risks Remain in Focus

Viatris (VTRS) shares fell about 7.7% as investors weighed execution and supply-disruption risks despite improved outlook. The company reported Q2 2026 revenue of about $3.8B (+5%) and adjusted EPS of $0.69, and raised 2026 guidance. It warned second-half revenue could be reduced by $100M to $150M due to Nashik remediation and FDA Form 483 issues, plus a GAAP net loss of about $119M tied largely to a planned Tyrvaya rights sale.

quiverquant.com6 min
AUG 6
$VTRSHighAI 9/10

Viatris Q2 2026 slides: strong beat drives guidance raise

Viatris (NASDAQ:VTRS) reported Q2 2026 adjusted EPS of $0.69 on revenues of $3.8 billion, topping analyst estimates of $0.61 and $3.67 billion, and raised full-year guidance. Updated 2026 outlook calls for revenues of $14.55B to $14.95B, adjusted EBITDA $4.30B to $4.50B, and adjusted EPS $2.45 to $2.59. Shares fell 3.29% to $17.07.

investing.com6 min
AUG 6
$VTRSHighAI 9/10

VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump

Viatris (VTRS) reported Q2 2026 adjusted EPS of 69 cents, above the Zacks consensus of 62 cents. Revenues rose 5% to $3.76 billion, exceeding the $3.68 billion estimate, driven by Developed Markets and a 21% jump in Greater China to $713.8 million. Viatris raised 2026 revenue guidance to $14.55-$14.95 billion and adjusted EPS to $2.45-$2.59.

finance.yahoo.com6 min
AUG 6
$VTRSHighAI 9/10

[VTRS Q2 2026 Earnings Call] Viatris Lifts Full-Year Forecast on 16% China Surge, Navigates $150M Supply Setback — BigGo Finance

Viatris (VTRS) reported Q2 2026 revenue of $3.8B, up 3.5% operationally, driven by a 16% Greater China surge and U.S. demand for complex generics and hormone patches. Management raised full-year guidance despite a $100–150M expected impact from Nashik plant supply disruptions. Viatris also cited FDA approvals and pipeline progress.

finance.biggo.com6 min